<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Heart transplantation in adults: Induction and maintenance of immunosuppressive therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Heart transplantation in adults: Induction and maintenance of immunosuppressive therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Heart transplantation in adults: Induction and maintenance of immunosuppressive therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael X Pham, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sharon A Hunt, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The goal of immunosuppression is to prevent or treat cardiac allograft rejection while minimizing drug toxicities as well as the major sequelae of immune suppression, namely infection and malignancy. Most clinically used immunosuppressive regimens consist of a combination of several agents used concurrently and the regimen design follows several general principles.</p><p>Immunosuppressive regimens can be classified as induction, maintenance, or antirejection. Induction regimens provide intense early postoperative immune suppression while maintenance regimens are used throughout the patient's life to prevent both acute and chronic rejection. This topic will review the induction and maintenance immunosuppressive regimens used in heart transplantation. The management of acute allograft rejection and allograft vasculopathy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3520.html" rel="external">"Heart transplantation in adults: Treatment of rejection"</a> and  <a class="medical medical_review" href="/z/d/html/3524.html" rel="external">"Heart Transplantation: Prevention and treatment of cardiac allograft vasculopathy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>Three general principles govern induction and maintenance immunosuppressive therapy regimens. The first principle is that immune reactivity and tendency toward graft rejection are highest early (within the first three to six months) after graft implantation and decrease with time. Thus, most regimens employ the highest intensity of immunosuppression immediately after surgery and decrease the intensity of therapy over the first year, eventually settling on the lowest maintenance levels of immunosuppression that are compatible with preventing graft rejection while minimizing drug toxicities in an individual patient. The second principle is to use low doses of several drugs with nonoverlapping toxicities in preference to higher (and more toxic) doses of fewer drugs whenever feasible. The third principle is to avoid over-immunosuppression, because it leads to a myriad of undesirable effects including susceptibility to infection and malignancy. (See  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a> and  <a class="medical medical_review" href="/z/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">INDUCTION THERAPY</span><span class="headingEndMark"> — </span>The overall strategy of deciding whether to use induction therapy and identifying an optimal regimen to achieve a state of early intense immunosuppression remains controversial. Approximately 40 to 50 percent of heart transplant programs currently employ a strategy of augmented immunosuppression (induction therapy) during the early postoperative period [<a href="#rid1">1</a>]. Several antilymphocyte antibodies that target specific epitopes on the surface of both B and T cells have been used as part of induction therapy.</p><p>The goal of induction therapy is to provide intense immunosuppression when the risk of allograft rejection is highest. From a clinical perspective, the main advantages of induction therapy are to allow delayed initiation of nephrotoxic immunosuppressive drugs in patients with compromised renal function prior to or following surgery and to provide some flexibility with respect to early glucocorticoid weaning or use of glucocorticoid-sparing maintenance regimens after transplantation [<a href="#rid2">2-4</a>].</p><p>However, the overall utility of induction is uncertain and data comparing induction protocols are limited. The decreased early rejection observed with induction therapy may be negated by an increase in late rejection after induction therapy is completed and by the potential for increased rates of infection and malignancy associated with such therapy [<a href="#rid5">5-11</a>]. However, patients at highest risk for fatal rejection, including younger patients, African American patients, patients with a high number of HLA mismatches, and patients supported with ventricular assist devices with high levels of preformed antibodies, may derive a benefit from induction therapy [<a href="#rid12">12</a>].</p><p>A Cochrane review included 22 randomized controlled trials investigating the use of T-cell antibody for induction [<a href="#rid13">13</a>]. Five trials, with a total of 606 participants, compared any type of induction versus no induction. The remaining trials compared various types of induction regimens against each other. No significant differences were found for any of the comparisons for outcomes of mortality, infection, posttransplant lymphoproliferative disorder, cancer, adverse events, or cardiac allograft vasculopathy.</p><p>In the Cochrane review, the only significant differences found were a reduction in the incidence of acute rejection among patients treated with interleukin-2 (IL-2) receptor antagonists compared with no induction and fewer rejection episodes among patients treated with polyclonal antibody induction compared with IL-2 receptor antagonist therapy, though the numbers of events were small so an effect of chance cannot be excluded. (See <a class="local">'Interleukin-2 receptor antagonists'</a> below and <a class="local">'Polyclonal antithymocyte antibodies'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Interleukin-2 receptor antagonists</span><span class="headingEndMark"> — </span>Use of interleukin-2 (IL-2) receptor antagonists for induction therapy has increased, and these drugs are now used in 30 percent of patients undergoing heart transplantation [<a href="#rid1">1</a>]. The currently available agent, <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> (Simulect), is a monoclonal antibody that selectively binds to the IL-2 receptor of T lymphocytes, blocks binding of IL-2 to the receptor complex, and exhibits its immunosuppressive effects by inhibiting IL-2-mediated T-lymphocyte proliferation.</p><p>The Cochrane review cited above included four trials with a total of 576 patients comparing IL-2 receptor antagonist versus no induction and found no significant difference in outcomes except possibly acute rejection [<a href="#rid13">13</a>]. Acute rejection occurred significantly less frequently with IL-2 receptor antagonist versus no induction when a fixed-effect model was used but not when a random-effects model was applied.</p><p class="headingAnchor" id="H5"><span class="h2">Polyclonal antithymocyte antibodies</span><span class="headingEndMark"> — </span>Polyclonal antibodies are derived by immunization of horses (ATGAM, also called lymphocyte <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a>) or rabbits (Thymoglobulin) with human thymocytes. These agents combined are employed in up to 20 percent of heart transplant recipients based upon the international transplant registry data [<a href="#rid1">1</a>].</p><p>These preparations contain antibodies directed against a wide variety of human T-cell antigens and cause rapid depletion of T lymphocytes by inducing complement-mediated cytolysis and cell-mediated opsonization in the spleen and liver. There are no head-to-head comparison trials of ATGAM and Thymoglobulin in heart transplantation, but data from the kidney transplant literature suggest that Thymoglobulin may result in a lower incidence of both short- and long-term acute rejection compared with ATGAM, possibly because of more profound and durable lymphopenia after Thymoglobulin administration [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy"</a>.)</p><p>The major acute side effects associated with this class of drugs include a serum sickness reaction characterized by fevers, chills, tachycardia, hypertension or hypotension, myalgias, and rash. The reaction is typically noticed during the first or second drug infusion and can be treated by temporarily stopping the drug infusion and restarting at a lower infusion rate. Premedication with intravenous glucocorticoids, antihistamines, antipyretics, and H2 blockers can prevent or reduce the severity of symptoms. Dose-dependent leukopenia (30 to 50 percent) and thrombocytopenia (30 to 40 percent) have also been observed and typically respond to dose reduction or drug discontinuation for severe cases (WBC &lt;2,000 cells/mm<sup>3</sup> or platelet count &lt;50,000 cells/mm<sup>3</sup>). These agents do not induce a host antibody response to horse or rabbit sera and can be re-used for the treatment of allograft rejection. Long-term side effects include a predisposition to opportunistic infections, particularly with cytomegalovirus and a possible increase in the incidence and aggressiveness of posttransplant malignancies [<a href="#rid11">11,16,17</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Alemtuzumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">Alemtuzumab</a> (Campath-1H) is a humanized rat monoclonal antibody that targets the CD52 antigen expressed on both T and B cells. It is used in fewer than 2 percent of heart transplant recipients [<a href="#rid1">1</a>]. This powerful cytolytic agent produces a profound lymphopenia that lasts for approximately six months and that may persist for up to three years in some individuals [<a href="#rid18">18</a>]. The agent was originally developed to treat chronic lymphocytic leukemia but has also been used as induction therapy in solid organ transplantation, mostly in kidney transplant recipients, where it has permitted use of lower intensity maintenance immunosuppression [<a href="#rid19">19</a>]. Early experience suggests that Campath may decrease the incidence of early (&lt;12 months) acute cellular rejection while allowing the use of lower intensity maintenance immunosuppression [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H8"><span class="h1">MAINTENANCE IMMUNOSUPPRESSIVE REGIMENS</span><span class="headingEndMark"> — </span>The strategies and drugs used for immune suppression have advanced considerably since the first heart transplant was performed in 1967. Beginning with the introduction of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in 1983, significant advances have been made in moving from drugs that provide broad and nonspecific immunosuppression to newer agents that provide more targeted immunosuppression through selective inhibition of lymphocyte activation and proliferation. This selectivity has resulted in a marked increase in patient survival due to a decrease in the incidence of both life-threatening opportunistic infections and rejection episodes. Most maintenance immunosuppressive protocols employ a three-drug regimen consisting of a calcineurin inhibitor (CNI; cyclosporine or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>), an antimetabolite agent (<a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil or less commonly <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>), and tapering doses of glucocorticoids over the first year posttransplantation. The commonly used drugs in heart transplantation and their toxicities are outlined  (<a class="graphic graphic_table graphicRef50962" href="/z/d/graphic/50962.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H9"><span class="h2">Calcineurin inhibitors</span><span class="headingEndMark"> — </span>Since the introduction of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in the early 1980s, CNIs have remained the cornerstone of maintenance immunosuppressive therapy in heart and other solid organ transplantation. These drugs exert their immunosuppressive effects by inhibiting calcineurin, which is normally responsible for the transcription of IL-2 and several other cytokines, including TNF alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma. The end result is blunting of T-lymphocyte activation and proliferation in response to alloantigens. The two available CNIs, cyclosporine and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, form complexes with different intracellular binding proteins, and these drug-protein complexes subsequently bind to and inhibit calcineurin. The drugs differ with respect to both efficacy and side effect profile. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Tacrolimus</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> (Prograf), previously known as FK-506, is a macrolide compound derived from the fungus Streptomyces tsukubaensis. It binds to a cytoplasmic protein called FK binding protein and inhibits calcineurin via a similar pathway to that of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>. The US Food and Drug Administration (FDA) originally approved the drug in 1995 for use in liver transplantation and later approved it for use in kidney (1997) and heart (2006) transplantation. Tacrolimus is the most widely used CNI.</p><p>Multiple single-center and multi-center randomized comparisons between de novo use of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> after heart transplantation have been reported [<a href="#rid21">21-27</a>]. As a whole, these trials have shown similar patient survival and a more favorable side effect profile with tacrolimus. For example, CNI-associated metabolic derangements appear to be significantly attenuated with tacrolimus use. Patients on tacrolimus, compared with cyclosporine, consistently had lower incidences of hypertension and hyperlipidemia. Two studies showed modest benefits with respect to renal function in the tacrolimus group [<a href="#rid27">27,28</a>], while one study demonstrated a higher incidence of posttransplant diabetes with tacrolimus [<a href="#rid21">21</a>]. With respect to efficacy, a few studies showed a decreased incidence of biopsy-proven acute rejection or drug-treated acute rejection in the tacrolimus treated patients [<a href="#rid21">21,28</a>].</p><p>In the largest head-to-head comparison of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, 314 de novo heart transplant recipients were randomized to either tacrolimus or microemulsion-based cyclosporine in combination with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and glucocorticoids [<a href="#rid21">21</a>]. All patients underwent induction therapy with either thymoglobulin or OKT3. Over 18 months of follow-up, patient survival was similar in both groups. However, patients in the tacrolimus group had a lower incidence of biopsy-proven moderate or severe acute cellular rejection at six months compared with the cyclosporine group (28 versus 42 percent, p = 0.013). Significant differences were also detected between the tacrolimus and cyclosporine group with respect to new onset diabetes mellitus (20 percent versus 11 percent), hypertension (66 versus 78 percent), and dyslipidemia (29 versus 40 percent). The incidence and patterns of infection, as well as renal function, were similar in the two groups.</p><p class="headingAnchor" id="H11"><span class="h3">Dosing and therapeutic drug monitoring</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> is available as oral capsules, liquid oral formulation, and as an injectable solution. The drug is typically given orally. When intravenous administration is required, approximately one-third of the daily oral dose should be given as a continuous infusion over 24 hours. Drug dosing is titrated to achieve therapeutic 12-hour trough levels for oral dosing and steady-state levels (approximately 1.4 times higher than trough levels) for intravenous dosing. In general, target trough levels are typically highest in the first two months (10 to 15 ng/mL), with reduced target levels later after transplantation (8 to 12 ng/mL during months 3 to 6, and 5 to 10 ng/mL after six months) [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Major toxicities</span><span class="headingEndMark"> — </span>Compared with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, use of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is associated with less hypertension and dyslipidemia. However, an increased frequency of new-onset diabetes mellitus has been observed in patients on tacrolimus compared with cyclosporine. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Cyclosporine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is a peptide derived from the fungus Tolypocladium inflatum that has powerful immunosuppressive properties. It binds to the cytoplasmic protein cyclophilin to inhibit calcineurin. The drug is available in several formulations. The older oil-based formulation called Sandimmune was characterized by variable and incomplete absorption. The newer modified formulations, including Gengraf and Neoral, are microemulsion formulations that result in improved and more reproducible drug absorption. In a randomized, multi-center, double-blind comparison of the oil-based (Sandimmune) versus the microemulsion (Neoral) cyclosporine formulations in de novo heart transplant recipients, the use of Neoral was associated with fewer rejection episodes requiring antilymphocyte antibody therapy compared with Sandimmune at 24 months (7 versus 18 percent, p = 0.002). Graft and patient survival were identical in both groups [<a href="#rid30">30</a>].</p><p>Due to their improved pharmacokinetic profile, the microemulsion preparations are generally preferred over the oil-based formulation. The two formulations are not considered bioequivalent, and patients should not be routinely switched from one to the other without close monitoring of drug levels.</p><p class="headingAnchor" id="H14"><span class="h3">Dosing and therapeutic drug monitoring</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is available as oil-based or microemulsion capsules, as an oral microemulsion solution, and as a concentrate for injection. When given intravenously, approximately one-third of the daily oral dose should be given as a continuous infusion over 24 hours. The drug is typically titrated to achieve therapeutic 12-hour trough levels for oral dosing and steady-state levels (approximately 2.6 times higher than trough levels) for intravenous dosing. In general, cyclosporine levels are kept highest in the first six months posttransplantation (275 to 375 ng/mL during the first six postoperative weeks, 200 to 350 ng/mL for weeks 6 to 12, and 150 to 300 ng/mL for months 3 to 6) and lowered in subsequent periods (150 to 250 ng/mL from month 6 onward) [<a href="#rid29">29</a>]. However, target drug levels should be individualized to balance a patient's risk of rejection with drug toxicities, particularly renal dysfunction, and long-term complications of immunosuppression (infections and malignancy).</p><p class="headingAnchor" id="H15"><span class="h3">Major toxicities</span><span class="headingEndMark"> — </span>The major toxicities of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> include kidney function impairment, hypertension, dyslipidemia, hypokalemia and hypomagnesemia, and neurotoxicity  (<a class="graphic graphic_table graphicRef50962" href="/z/d/graphic/50962.html" rel="external">table 1</a>). Gingival hyperplasia and hirsutism are two additional side effects that are unique to cyclosporine and can be especially bothersome in young patients. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">ANTIMETABOLITES</span><span class="headingEndMark"> — </span>The antimetabolites, or antiproliferative agents, interfere with the synthesis of nucleic acids and exert their immunosuppressive effects by inhibiting the proliferation of both T and B lymphocytes.</p><p class="headingAnchor" id="H17"><span class="h2">Azathioprine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> (Imuran) is a prodrug that is first rapidly hydrolyzed in the blood to its active form, <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a>, and subsequently converted to a purine analogue, thio-inosine-monophosphate. This antimetabolite is incorporated into DNA and inhibits further nucleotide synthesis, thereby preventing mitosis and proliferation of rapidly dividing cells such as activated T and B lymphocytes. This drug is typically used as an adjunctive immunosuppressive agent with either glucocorticoids or, more commonly, in conjunction with a calcineurin inhibitor. A typical dose is 1 to 3 mg/kg/day, and the maximum dose is 200 mg/day. The dose of azathioprine is adjusted to keep the white blood cell count at or slightly above 3000/mm<sup>3</sup>. The major side effects include dose-dependent myelosuppression, particularly leukopenia. Azathioprine should be temporarily withheld if the white cell count falls below 3000/mm<sup>3</sup> or drops by 50 percent compared with the previous value. Other potentially serious side effects include hepatotoxicity and pancreatitis.</p><p class="headingAnchor" id="H18"><span class="h2">Mycophenolate mofetil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil (MMF; Cellcept) has replaced <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> as the preferred antimetabolite agent. It is also a prodrug that is rapidly hydrolyzed to its active form, mycophenolic acid (MPA). MPA is a reversible inhibitor of inosine monophosphate dehydrogenase, a critical enzyme for the de-novo synthesis of guanine nucleotides. Lymphocytes lack a key enzyme in the guanine salvage pathway and are dependent upon the de novo pathway for the production of purines necessary for RNA and DNA synthesis. Therefore, both T- and B-lymphocytes proliferation is selectively inhibited.</p><p>In a multicenter, active-controlled, randomized trial, MMF was compared with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> when used in conjunction with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and glucocorticoids in 650 de novo heart transplant recipients. Because an intravenous form of the study drug (MMF) was not available at the time of the trial, 11 percent of the patients withdrew before receiving the drug. Survival and rejection were similar in both groups when analyzed in an intention-to-treatment manner. However, among treated patients, MMF was associated with a significant reduction in both mortality (6 versus 11 percent, p = 0.031) and in the incidence of treatable rejection (66 versus 74 percent, p = 0.026) at one year [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H19"><span class="h3">Dosing and therapeutic drug monitoring</span><span class="headingEndMark"> — </span>MMF is available as a tablet or capsule, oral suspension (liquid), and as a powder for injection. The intravenous solution is given at the same oral dose as a two-hour infusion every 12 hours. The drug is typically administered at a starting dose of 1000 to 1500 mg twice daily and subsequently decreased as needed in response to leukopenia and gastrointestinal intolerance.</p><p>Routine monitoring of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> levels is not recommended [<a href="#rid29">29,32</a>]. Monitoring of mycophenolic acid (MPA) levels may be helpful in patients with high risk for rejection or adverse effects [<a href="#rid33">33-35</a>]; levels can also be useful to assess compliance when that is a concern. Some centers target MPA trough levels between 2 to 5 mcg/mL. However, MPA trough levels are poorly correlated with AUC [<a href="#rid36">36</a>]. In patients receiving mycophenolate mofetil at steady-state, limited sampling strategies to estimate the area under the concentration-time curve (AUC<sub>0-12h</sub>) were found to correlate with a full AUC measurement [<a href="#rid37">37-39</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Major toxicities</span><span class="headingEndMark"> — </span>MMF is not nephrotoxic and causes less bone marrow suppression compared with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>. The main side effects include dose-related leukopenia and gastrointestinal toxicities such as nausea, gastritis, and diarrhea. A possible association between MMF and Progressive Multifocal Leukoencephalopathy (PML) has been reported [<a href="#rid40">40</a>]. The drug is contraindicated during pregnancy due to the risk of miscarriage and teratogenicity, and women of childbearing potential should not take MMF without appropriate birth control measures. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Mycophenolate mofetil'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Mycophenolate sodium</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> sodium (EC-MPS) is an enteric coated, delayed release salt of mycophenolic acid developed to improve the upper gastrointestinal tolerability of mycophenolate. Mycophenolic sodium is available in 180 mg and 360 mg enteric coated tablets. Because of this coating, the tablet should <strong>NOT</strong> be crushed. The following conversions between MMF and mycophenolate sodium should provide equimolar amounts of MPA:</p><p class="bulletIndent1"><span class="glyph">●</span>1000 mg MMF = 720 mg <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> sodium</p><p class="bulletIndent1"><span class="glyph">●</span>1500 mg MMF = 1080 mg <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> sodium</p><p></p><p>Thus, a typical starting dose is 720 to 1080 twice daily. Single- and multi-center studies in de novo heart transplant recipients have shown that EC-MPS is therapeutically similar to MMF with respect to prevention of treatment failure (defined as biopsy-proven and treated acute rejection episodes, graft loss, or death). However, significantly fewer patients in the EC-MPS group required dose reductions during treatment [<a href="#rid41">41,42</a>].</p><p>Limited sampling strategies to estimate the area under the concentration-time curve for <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil are not directly applicable to patients receiving mycophenolate sodium [<a href="#rid43">43</a>]. Limited sampling strategies to estimate full AUC have been proposed for patients treated with enteric-coated mycophenolate sodium [<a href="#rid44">44,45</a>]; however, consensus is lacking on the utility of these methods.</p><p class="headingAnchor" id="H22"><span class="h1">PROLIFERATION SIGNAL INHIBITORS</span><span class="headingEndMark"> — </span>A new class of drugs known as proliferation signal inhibitors, or mammalian target of rapamycin (mTOR) inhibitors, has been used in selected patients with kidney function impairment, cardiac allograft vasculopathy, or malignancies in an attempt to reverse or slow progression of these conditions. However, the high incidence of drug-related adverse effects, including delayed sternal wound healing after transplantation, may limit the widespread use of these agents as de novo therapy following transplantation [<a href="#rid46">46-48</a>].</p><p>The two drugs in this class, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, have similar mechanisms of action. They are structurally similar to <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and also bind to the FK binding protein. However, they exert their immunosuppressive effects via a calcineurin-independent mechanism. The drug-immunophilin complex inhibits a protein kinase in the cytoplasm called mammalian target of rapamycin (mTOR). mTOR is involved in the transduction signals from the IL-2 receptor to the nucleus, causing cell cycle arrest at the G1 to S phase. The consequence of mTOR inhibition is inhibition of both T- and B-cell proliferation in response to cytokine signals.</p><p class="headingAnchor" id="H23"><span class="h2">Sirolimus</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> (Rapamune) is a macrolide antibiotic derived from the fungus Streptomyces hygroscopicus. The efficacy of sirolimus as an alternative to <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> was evaluated in a prospective, open-label, randomized trial of 136 de novo heart transplant recipients. Patients were randomized 2:1 to receive one of two sirolimus doses (3 or 5 mg) or to azathioprine. Sirolimus doses were subsequently adjusted in both groups to achieve similar target blood levels. All patients received concurrent immunosuppression with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and glucocorticoids. Compared with azathioprine, the proportion of patients with a biopsy-proven moderate to severe acute cellular rejection episode at six months was lower in both the 3 mg/day (32 versus 57 percent, p = 0.027) and 5 mg/day sirolimus groups (33 versus 57 percent, p = 0.013). Additionally, the progression of cardiac allograft vasculopathy, as defined by intravascular ultrasound, was significantly reduced in the sirolimus group at both six months and two years. Patient survival at 12 months was comparable among groups [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H24"><span class="h3">Dosing and therapeutic drug monitoring</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> is available in a liquid or tablet formulation. When used in conjunction with cyclosporine-modified capsules (Gengraf or Neoral), sirolimus should be given four hours after <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> administration to minimize the pharmacokinetic interaction between the two drugs. Dosing is typically adjusted to achieve serum trough levels of 4 to 12 ng/mL when used with a concurrent calcineurin inhibitor (CNI) and 8 to 14 ng/mL when used as part of a CNI-free regimen [<a href="#rid29">29,49</a>]. Target ranges may vary depending upon the assay (immunoassay versus chromatographic) used, so clinicians should be familiar with the reference range for the assay used at their institutions.</p><p class="headingAnchor" id="H25"><span class="h3">Major toxicities</span><span class="headingEndMark"> — </span>The most common drug-related toxicities include hyperlipidemia, oral ulcerations, lower extremity edema, and bone marrow suppression with leukopenia, thrombocytopenia, and anemia [<a href="#rid48">48</a>]. Postsurgical wound healing complications, as well as an increase in the incidence of pleural and pericardial effusions requiring drainage, have also been reported [<a href="#rid46">46,50</a>]. Finally, rare but serious cases of sirolimus-related pulmonary toxicity have been described [<a href="#rid51">51-53</a>].</p><p><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> has no inherent nephrotoxic effects but can potentiate the nephrotoxic effects of CNIs. Therefore, when these agents are used together, the dose of the CNI should be reduced by approximately 25 percent. Additionally, moderate or higher proteinuria (≥300 mg/day) has been observed in 26 percent of patients after the first year following conversion from a CNI, particularly in patients with preexisting proteinuria prior to conversion. The development of proteinuria after conversion has been associated with worsening renal function, cardiac allograft vasculopathy progression, and increased all-cause mortality [<a href="#rid54">54</a>]. In our practice, we order a random morning urine collection and calculate a spot protein to creatinine ratio (UPCR) as an estimate of 24-hour protein excretion because collection of 24-hour urine samples is cumbersome and prone to collection errors. We check the UPCR prior to sirolimus conversion and at 4, 8, and 12 months and yearly thereafter. We place patients who have preexisting proteinuria, or who develop proteinuria after conversion, on angiotensin converting enzyme inhibitors, and discontinue sirolimus if the protein excretion is &gt;1000 mg/day.</p><p class="headingAnchor" id="H26"><span class="h2">Everolimus</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> (Zortress) is an analog of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> that was approved for clinical use in the United States for prevention of rejection in kidney and liver transplantation. The main difference between sirolimus and everolimus is that the half-life of everolimus (30 hours) is approximately half that of sirolimus (60 hours).</p><p><a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> was studied in a 24-month, multi-center, randomized, open-label, noninferiority study involving 721 de novo heart transplant recipients [<a href="#rid55">55</a>]. Patients were randomized to one of two everolimus drug exposures (1.5 mg/day or 3.0 mg/day in divided doses) with reduced-dose <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, or to <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) with standard-dose cyclosporine. Patients received glucocorticoids with or without induction therapy according to individual transplant center protocols. Enrollment into the higher dose (3.0 mg/day) everolimus arm was stopped prematurely due to a higher incidence of early mortality, mostly due to infections, in this group. Everolimus was found to be noninferior to MMF with respect to the primary efficacy end point of biopsy-proven acute cellular rejection, acute rejection with hemodynamic compromise, graft loss or retransplantation, death, or loss to follow-up. Patients on everolimus had reduced progression of coronary artery intimal wall thickening on intravascular ultrasound at 12 months posttransplantation. More nonfatal serious adverse events, particularly pericardial effusions, and a higher rate of drug discontinuations due to adverse events were reported in the everolimus group compared with the MMF group. Finally, everolimus was noted to be inferior to MMF with respect to renal function, but a post hoc analysis indicated that this finding was largely driven by a subset of study centers that were not successful in reducing the cyclosporine exposure in the everolimus group.</p><p class="headingAnchor" id="H350933770"><span class="h3">Use within the first three months posttransplantation</span><span class="headingEndMark"> — </span>The United States Food and Drug Administration issued a black box warning for <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> because of the increased risk of mortality observed within the first three months posttransplantation among patients started on the higher dose (3.0 mg/day) of everolimus as de novo immunosuppression. Therefore, the use of everolimus early after heart transplantation is not recommended.</p><p class="headingAnchor" id="H350933781"><span class="h3">Dosing and therapeutic drug monitoring</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> is available in a tablet formulation. The starting dose is 0.75 mg twice daily, adjusted according to trough blood levels. Target blood levels are 3 to 8 ng/mL when used in combination with a CNI and 6 to 10 ng/mL when used as part of a CNI-free regimen [<a href="#rid29">29,56</a>].</p><p class="headingAnchor" id="H350933788"><span class="h3">Major toxicities</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> has a similar toxicity profile compared with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>. Although no head to head comparison between the two drugs exists, clinical observations suggest that patients on everolimus may experience less severe side effects compared with those taking sirolimus.</p><p class="headingAnchor" id="H27"><span class="h1">GLUCOCORTICOIDS</span><span class="headingEndMark"> — </span>Glucocorticoids are nonspecific antiinflammatory agents that interrupt multiple steps in immune activation, including antigen presentation, cytokine production, and proliferation of lymphocytes. Although glucocorticoids are highly effective for the prevention and treatment of acute rejection, their long-term use is associated with a number of adverse effects, including new onset or worsening diabetes mellitus, hyperlipidemia, hypertension, fluid retention, myopathy, osteoporosis, and a predisposition toward opportunistic infections. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>Glucocorticoids are begun upon separation from cardiopulmonary bypass after the transplant surgery. <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">Methylprednisolone</a> is typically given at an initial dose of 500 mg, followed by 125 mg every eight hours during the first 24 hours after transplantation. Subsequently, oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> is started at a dose of up to 1 mg/kg/day in two divided doses, and subsequently tapered to 0 to 0.05 mg/kg/day by 6 to 12 months. (See  <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">"Glucocorticoid effects on the immune system"</a>.)</p><p>Thus, while most programs employ glucocorticoids as one of the three maintenance immunosuppressive agents, they are used in relatively high doses in the early postoperative period but then tapered to low doses or discontinued altogether after the first 6 to 12 months [<a href="#rid57">57-60</a>]. Certain low-risk patients may tolerate earlier (within one to two months posttransplantation) steroid withdrawal without long-term adverse consequences [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H28"><span class="h1">TRENDS IN DRUG USE</span><span class="headingEndMark"> — </span>International trends in the use of maintenance immunosuppressive agents at one year posttransplantation include a steady increase in <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> use over <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> since 2005 [<a href="#rid1">1</a>]. At one year post-heart transplant, tacrolimus is currently the most widely prescribed calcineurin inhibitor (CNI; 95 percent of patients) in heart transplantation. <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil (MMF) and mycophenolate sodium remain the predominant antimetabolite agents (91 percent of patients). The use of the antiproliferative agents <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> has remained low (9 percent of patients). Finally, 83 percent of patients remained on some amount of glucocorticoid at one year posttransplantation. With respect to drug combinations, use of tacrolimus and MMF with or without steroids was most common (78 percent of patients) during the first year posttransplantation. For additional information, see the slides <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fishltregistries.org%2Fregistries%2Fslides.asp&amp;token=MDXro05ivebLvlMrwIKPNZNOwMeCI5s%2B6UW2zMxK6Hf3rsDg0xIG3r0yhm70Bo3k&amp;TOPIC_ID=3530" target="_blank">Adult Heart Transplantation Statistics</a>.</p><p class="headingAnchor" id="H29"><span class="h1">SPECIAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>Most programs employ a standard de novo immunosuppressive regimen immediately after transplantation. Once stabilized on a particular regimen, immunosuppressive agents are not routinely altered except in response to significant drug toxicities or posttransplant complications. The most common changes in drug regimens and their rationale are described below.</p><p class="headingAnchor" id="H30"><span class="h2">Refractory or recurrent rejection</span><span class="headingEndMark"> — </span>Following one or more episodes of acute rejection, many centers will attempt to optimize a patient's baseline immunosuppression. Some programs that routinely utilize <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> as the de-novo calcineurin inhibitor (CNI) of choice will switch patients to <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. Patients previously on <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> may be converted to the newer and more effective antimetabolite agent, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF). Finally, patients on either azathioprine or MMF may be converted to the proliferation signal inhibitor <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>. (See  <a class="medical medical_review" href="/z/d/html/3520.html" rel="external">"Heart transplantation in adults: Treatment of rejection"</a>.)</p><p class="headingAnchor" id="H31"><span class="h2">Kidney function impairment</span><span class="headingEndMark"> — </span>Several renal sparing protocols are employed to slow or reverse the progression of CNI-mediated kidney function impairment. Strategies include use of the proliferation signal inhibitors in lieu of the antimetabolite agents to allow minimization of the CNI dose or complete withdrawal of CNIs in favor of using the combination of a proliferation signal inhibitor and MMF (CNI-free regimens). Both strategies have resulted in significant improvements in renal function [<a href="#rid63">63-70</a>]. However, the use of CNI-free regimens may provide additional improvements in renal function compared with low-dose CNI strategies in carefully selected patients who are at low risk of rejection and do not have significant proteinuria (≥1000 mg/day) at baseline [<a href="#rid71">71-73</a>]. Of note, use of a CNI-free regimen within the first six-month postoperative period or in patients at higher risk for rejection should be done with caution due to the observed increased incidence of biopsy-proven rejection in these settings [<a href="#rid47">47,56,73</a>].</p><p class="headingAnchor" id="H32"><span class="h2">Cardiac allograft vasculopathy</span><span class="headingEndMark"> — </span>Because mammalian target of rapamycin (mTOR) also signals smooth muscle cell and endothelial cell proliferation in response to growth factors, the proliferation signal inhibitors have been used to slow allograft vascular disease progression and to reduce the incidence of clinically significant cardiac events when used in a de novo setting after heart transplantation or in patients with established disease on the basis of intravascular ultrasound or coronary angiography [<a href="#rid48">48,74-76</a>]. (See  <a class="medical medical_review" href="/z/d/html/3524.html" rel="external">"Heart Transplantation: Prevention and treatment of cardiac allograft vasculopathy"</a>.)</p><p class="headingAnchor" id="H33"><span class="h2">Malignancies</span><span class="headingEndMark"> — </span>Observational data, mostly from the kidney transplant literature, suggest that the proliferation signal inhibitors <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> may reduce the incidence of posttransplant skin and solid organ malignancies [<a href="#rid77">77-79</a>]. Limited data also suggest that sirolimus monotherapy may cause regression of certain skin tumors, such as Kaposi sarcoma, in kidney transplant recipients [<a href="#rid80">80</a>]. In a randomized clinical trial of kidney transplant recipients with a prior history of cutaneous squamous-cell carcinoma, patients who were switched from a CNI to sirolimus had a lower risk of subsequent skin cancers [<a href="#rid81">81</a>]. Postulated mechanisms responsible for this antitumor effect include direct antiproliferative actions of these drugs on tumor growth and angiogenesis, as well as facilitation of CNI dose reduction or withdrawal [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H2241509969"><span class="h2">COVID-19</span><span class="headingEndMark"> — </span>Maintenance immunosuppression in cardiac transplant recipients with COVID-19 is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/127537.html" rel="external">"COVID-19: Evaluation and management of cardiac disease in adults", section on 'Cardiac transplantation'</a>.)</p><p class="headingAnchor" id="H34"><span class="h2">Side effects</span><span class="headingEndMark"> — </span>Certain side effects, such as hirsutism or gingival hyperplasia, are unique to <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>. Therefore, individuals who develop severe forms of these complications on cyclosporine may be converted to <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. Patients with persistent upper gastrointestinal symptoms on MMF despite an initial dose reduction may better tolerate enteric-coated <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> sodium. Severe cases of sirolimus-related lower extremity edema and rare but potentially life-threatening episodes of sirolimus-related interstitial pneumonitis will prompt most centers to discontinue the drug.</p><p class="headingAnchor" id="H35"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>Clinicians involved in the care of heart transplant recipients should be aware of the potential for drug interactions when other agents are added to or deleted from a patient's medical regimen [<a href="#rid83">83</a>]. A common juncture for such changes is when a transplant recipient requires antiinfective therapy.</p><p>A list of the most common and clinically important drug interactions is presented in the table  (<a class="graphic graphic_table graphicRef78597" href="/z/d/graphic/78597.html" rel="external">table 2</a>). Specific interactions of antirejection agents with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate. This program can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.</p><p>Drug interactions involving immunosuppressive agents are numerous and medication regimens for transplant recipients are complex. While most drug interactions are not clinically significant and few combinations are absolutely contraindicated, many can create serious consequences in the absence of appropriate monitoring and dose adjustments. Preventable consequences can include organ rejection or acute kidney injury from supratherapeutic levels of calcineurin inhibitors (CNIs). An evaluation by a clinical pharmacist with transplant expertise may be valuable in some instances.</p><p>One combination involving <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> should be avoided. Allopurinol inhibits the activity of xanthine oxidase, which is involved in the metabolism of azathioprine, resulting in high levels of the active metabolite <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a> and possible severe bone marrow suppression if the two drugs are used together. <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> is an alternative to azathioprine in patients who require allopurinol therapy.</p><p class="headingAnchor" id="H36"><span class="h2">Pharmacokinetic drug interactions</span><span class="headingEndMark"> — </span>Pharmacokinetic drug interactions occur when a drug changes the immunosuppressive drug blood concentration profile, by interfering with the absorption, distribution, metabolism, or elimination of the immunosuppressive agent. Most clinically important pharmacokinetic drug interactions occur due to altered drug metabolism. CNIs and proliferation signal inhibitors are extensively metabolized by the cytochrome P-450 3A4 enzyme pathway in the liver so their blood levels are affected by drugs that induce or inhibit this pathway.</p><p>Drugs that induce the P-450 3A4 pathway result in enhanced metabolism of CNIs and proliferation signal inhibitors, thus lowering their blood levels and clinical effectiveness. Strong inducers of the cytochrome P-450 3A4 pathway include certain antiseizure medications (<a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>), the antitubercular agent <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, certain antiretroviral agents (<a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a>), and the herbal agent St. John's wort.</p><p>Conversely, drugs that inhibit the cytochrome P-450 3A4 enzyme pathway result in decreased metabolism of CNIs and proliferation signal inhibitors, thereby increasing their blood levels and potentiating their toxicities. Many drugs inhibit cytochrome P-450 3A4 [<a href="#rid84">84</a>]. Common inhibitors include the macrolide antibiotics, azole antifungal agents, nondihydropyridine calcium channel blockers, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, and several antiretroviral drugs.</p><p class="headingAnchor" id="H37"><span class="h2">Pharmacodynamic drug interactions</span><span class="headingEndMark"> — </span>Pharmacodynamic drug interactions occur when a drug modulates an immunosuppressive agent's effect at a given blood concentration, either increasing or diminishing the immunosuppressive drug's therapeutic and/or toxic effects. For example, concurrent use of <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a>, <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a>, or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> can potentiate the myelosuppressive effects of the antimetabolite agents and proliferation signal inhibitors. Another example of additive nephrotoxicity is observed when amphotericin B, aminoglycosides, <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">foscarnet</a>, or nonsteroidal antiinflammatory agents are used with CNIs.</p><p class="headingAnchor" id="H29727816"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3439.html" rel="external">"Patient education: Heart transplantation (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H38"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Induction and maintenance immunosuppressive regimens after heart transplantation vary according to transplant center experience and recipient characteristics (renal function, baseline risk of rejection, and individual drug tolerability). However, most regimens adhere to the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span>The use of routine induction therapy remains controversial. (See <a class="local">'Induction therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Induction therapy may be of benefit in the subset of patients with the highest risk of acute rejection (presensitized patients, young patients, female patients, and African American patients) and in patients with impaired renal function to allow delayed initiation of calcineurin inhibitors (CNIs) posttransplantation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Commonly used induction agents include the interleukin-2 receptor antagonist <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> and polyclonal antithymocyte antibodies (thymoglobulin).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most modern immunosuppressive regimens consist of a two- or three-drug regimen, including a CNI (typically <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>), an antimetabolite agent (typically <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil), and tapering doses of glucocorticoids over the first year.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> are both highly effective agents, evidence from clinical trials suggests that tacrolimus-based immunosuppression may offer an advantage over cyclosporine-based regimens with respect to decreased rates of acute rejection and an overall more favorable metabolic derangement profile (decreased incidence of hypertension and hyperlipidemia but higher incidence of posttransplant diabetes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The proliferation signal inhibitors <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> are typically used in patients with cardiac allograft vasculopathy or kidney function impairment. Due to their inhibitory effects on smooth muscle proliferation and absence of intrinsic nephrotoxicity, they have been useful for slowing disease progression in these settings.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The use of <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> within the first three months after heart transplantation is not recommended due to a higher incidence of mortality due to infections.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When used in conjunction with a CNI (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>), the dose of the CNI should be reduced by 25 percent to reduce the risk of nephrotoxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Proliferation signal inhibitors should not be started in patients with significant proteinuria (≥1000 mg/day) and should be discontinued if significant proteinuria develops.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The high incidence of drug-related adverse effects, including lower extremity edema, oral ulcerations, and poor wound healing, may limit generalized use of these agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CNIs and proliferation signal inhibitors are heavily metabolized by the cytochrome P450 3A4 pathway and therefore are susceptible to numerous drug interactions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians managing heart transplant patients should become familiar with the common agents that can increase immunosuppressive drug levels (eg, <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>), decrease drug levels (eg, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, St. John's wort), or potentiate the toxic properties of immunosuppressive agents (eg, nephrotoxicity associated with nonsteroidal antiinflammatory agents and aminoglycoside antibiotics). When these drugs are added to or deleted from a patient's baseline regimen, immunosuppressive drug levels and renal function should be carefully monitored.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant 2019; 38:1056.</a></li><li><a class="nounderline abstract_t">Rosenberg PB, Vriesendorp AE, Drazner MH, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 2005; 24:1327.</a></li><li><a class="nounderline abstract_t">Yamani MH, Taylor DO, Czerr J, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant 2008; 22:76.</a></li><li><a class="nounderline abstract_t">Cantarovich M, Giannetti N, Barkun J, Cecere R. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 2004; 78:779.</a></li><li><a class="nounderline abstract_t">Adamson R, Obispo E, Dychter S, et al. Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience. Transplant Proc 1998; 30:1107.</a></li><li><a class="nounderline abstract_t">Johnson MR, Mullen GM, O'Sullivan EJ, et al. Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. Am J Cardiol 1994; 74:261.</a></li><li><a class="nounderline abstract_t">Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323:1723.</a></li><li><a class="nounderline abstract_t">Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4:222.</a></li><li><a class="nounderline abstract_t">Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 342:613.</a></li><li><a class="nounderline abstract_t">Prieto M, Lake KD, Pritzker MR, et al. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients. J Heart Lung Transplant 1991; 10:901.</a></li><li><a class="nounderline abstract_t">Rinaldi M, Pellegrini C, D'Armini AM, et al. Neoplastic disease after heart transplantation: single center experience. Eur J Cardiothorac Surg 2001; 19:696.</a></li><li><a class="nounderline abstract_t">Higgins R, Kirklin JK, Brown RN, et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Heart Lung Transplant 2005; 24:392.</a></li><li><a class="nounderline abstract_t">Penninga L, Møller CH, Gustafsson F, et al. Immunosuppressive T-cell antibody induction for heart transplant recipients. Cochrane Database Syst Rev 2013; :CD008842.</a></li><li><a class="nounderline abstract_t">Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008; 86:947.</a></li><li><a class="nounderline abstract_t">Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67:1011.</a></li><li><a class="nounderline abstract_t">El-Hamamsy I, Stevens LM, Carrier M, et al. Incidence and prognosis of cancer following heart transplantation using RATG induction therapy. Transpl Int 2005; 18:1280.</a></li><li><a class="nounderline abstract_t">Carrier M, Leblanc MH, Perrault LP, et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 2007; 26:258.</a></li><li><a class="nounderline abstract_t">Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006; 81:81.</a></li><li><a class="nounderline abstract_t">Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006; 81:1361.</a></li><li><a class="nounderline abstract_t">Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 2010; 10:382.</a></li><li><a class="nounderline abstract_t">Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial. Am J Transplant 2006; 6:1387.</a></li><li><a class="nounderline abstract_t">Groetzner J, Meiser BM, Schirmer J, et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? Transplant Proc 2001; 33:1461.</a></li><li><a class="nounderline abstract_t">Meiser BM, Uberfuhr P, Fuchs A, et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998; 17:782.</a></li><li><a class="nounderline abstract_t">Rinaldi M, Pellegrini C, Martinelli L, et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. J Heart Lung Transplant 1997; 16:1001.</a></li><li><a class="nounderline abstract_t">Reichart B, Meiser B, Viganò M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998; 17:775.</a></li><li><a class="nounderline abstract_t">Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18:336.</a></li><li><a class="nounderline abstract_t">Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377.</a></li><li><a class="nounderline abstract_t">Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006; 25:434.</a></li><li><a class="nounderline abstract_t">Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29:914.</a></li><li><a class="nounderline abstract_t">Eisen HJ, Hobbs RE, Davis SF, et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months after transplantation. Transplantation 2001; 71:70.</a></li><li><a class="nounderline abstract_t">Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66:507.</a></li><li><a class="nounderline abstract_t">Chapman JR. The KDIGO clinical practice guidelines for the care of kidney transplant recipients. Transplantation 2010; 89:644.</a></li><li><a class="nounderline abstract_t">Roan JN, Chou CH, Hsu CH, et al. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. Ann Transplant 2013; 18:43.</a></li><li><a class="nounderline abstract_t">van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28:145.</a></li><li><a class="nounderline abstract_t">Zuk DM, Pearson GJ. Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients--a systematic review. Transplant Rev (Orlando) 2009; 23:171.</a></li><li><a class="nounderline abstract_t">Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 2006; 82:1004.</a></li><li><a class="nounderline abstract_t">Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48:1497.</a></li><li><a class="nounderline abstract_t">Tutor-Crespo MJ, Hermida J, Romero R, Tutor JC. Two sampling time profiles for the abbreviated estimation  of mycophenolic acid area under the curve in adult  renal transplant recipients treated with mycophenolate  mofetil and concomitant tacrolimus. J Clin Pharm Ther 2009; 34:531.</a></li><li><a class="nounderline abstract_t">Gaies E, Ben Sassi M, El Jebari H, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in Tunisian renal transplant patients. Nephrol Ther 2017; 13:460.</a></li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm072438.htm (Accessed on June 12, 2009).</li><li><a class="nounderline abstract_t">Kobashigawa JA, Renlund DG, Gerosa G, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006; 25:935.</a></li><li><a class="nounderline abstract_t">Lehmkuhl H, Hummel M, Kobashigawa J, et al. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil. Transplant Proc 2008; 40:953.</a></li><li><a class="nounderline abstract_t">Kiang TK, Ensom MH. Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update. Expert Opin Drug Metab Toxicol 2016; 12:545.</a></li><li><a class="nounderline abstract_t">Jia Y, Peng B, Li L, et al. Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium. Ther Drug Monit 2017; 39:29.</a></li><li><a class="nounderline abstract_t">David-Neto E, Triboni AH, Ramos F, et al. Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. Ther Drug Monit 2018; 40:411.</a></li><li><a class="nounderline abstract_t">Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6:986.</a></li><li><a class="nounderline abstract_t">González-Vílchez F, de Prada JA, Exposito V, et al. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant 2008; 27:1135.</a></li><li><a class="nounderline abstract_t">Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110:2694.</a></li><li><a class="nounderline abstract_t">Groetzner J, Kaczmarek I, Schulz U, et al. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 2009; 87:726.</a></li><li><a class="nounderline abstract_t">Zakliczynski M, Nozynski J, Kocher A, et al. Surgical wound-healing complications in heart transplant recipients treated with rapamycin. Wound Repair Regen 2007; 15:316.</a></li><li><a class="nounderline abstract_t">García-Luque A, Cordero E, Torelló J, et al. Sirolimus-associated pneumonitis in heart transplant recipients. Ann Pharmacother 2008; 42:1143.</a></li><li><a class="nounderline abstract_t">Khalife WI, Kogoj P, Kar B. Sirolimus-induced alveolar hemorrhage. J Heart Lung Transplant 2007; 26:652.</a></li><li><a class="nounderline abstract_t">Delgado JF, Torres J, José Ruiz-Cano M, et al. Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant 2006; 25:1171.</a></li><li><a class="nounderline abstract_t">Asleh R, Alnsasra H, Lerman A, et al. Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients. Am J Transplant 2021; 21:626.</a></li><li><a class="nounderline abstract_t">Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 2013; 13:1203.</a></li><li><a class="nounderline abstract_t">Andreassen AK, Andersson B, Gustafsson F, et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant 2014; 14:1828.</a></li><li><a class="nounderline abstract_t">Miller LW, Wolford T, McBride LR, et al. Successful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant 1992; 11:431.</a></li><li><a class="nounderline abstract_t">Olivari MT, Jessen ME, Baldwin BJ, et al. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. J Heart Lung Transplant 1995; 14:127.</a></li><li><a class="nounderline abstract_t">Kobashigawa JA, Stevenson LW, Brownfield ED, et al. Initial success of steroid weaning late after heart transplantation. J Heart Lung Transplant 1992; 11:428.</a></li><li><a class="nounderline abstract_t">Teuteberg JJ, Shullo M, Zomak R, et al. Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection. Clin Transplant 2008; 22:730.</a></li><li><a class="nounderline abstract_t">Taylor DO, Bristow MR, O'Connell JB, et al. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant 1996; 15:1039.</a></li><li><a class="nounderline abstract_t">Renlund DG, O'Connell JB, Gilbert EM, et al. Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. J Heart Transplant 1987; 6:71.</a></li><li><a class="nounderline abstract_t">Gustafsson F, Ross HJ, Delgado MS, et al. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J Heart Lung Transplant 2007; 26:998.</a></li><li><a class="nounderline abstract_t">Raichlin E, Khalpey Z, Kremers W, et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 2007; 84:467.</a></li><li><a class="nounderline abstract_t">Rothenburger M, Teerling E, Bruch C, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 2007; 26:250.</a></li><li><a class="nounderline abstract_t">Bestetti R, Theodoropoulos TA, Burdmann EA, et al. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up. Transplantation 2006; 81:692.</a></li><li><a class="nounderline abstract_t">Fernandez-Valls M, Gonzalez-Vilchez F, de Prada JA, et al. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center. Transplant Proc 2005; 37:4021.</a></li><li><a class="nounderline abstract_t">Kushwaha SS, Khalpey Z, Frantz RP, et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005; 24:2129.</a></li><li><a class="nounderline abstract_t">Hunt J, Lerman M, Magee MJ, et al. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 2005; 24:1863.</a></li><li><a class="nounderline abstract_t">Groetzner J, Kaczmarek I, Landwehr P, et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004; 25:333.</a></li><li><a class="nounderline abstract_t">Gleissner CA, Doesch A, Ehlermann P, et al. Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy. Am J Transplant 2006; 6:2750.</a></li><li><a class="nounderline abstract_t">Potter BJ, Giannetti N, Edwardes MD, et al. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients. Clin Transplant 2007; 21:305.</a></li><li><a class="nounderline abstract_t">Barten MJ, Hirt SW, Garbade J, et al. Comparing everolimus-based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from six months after heart transplantation: the randomized MANDELA study. Am J Transplant 2019.</a></li><li><a class="nounderline abstract_t">Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847.</a></li><li><a class="nounderline abstract_t">Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108:48.</a></li><li><a class="nounderline abstract_t">Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007; 116:2726.</a></li><li><a class="nounderline abstract_t">Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18:446.</a></li><li><a class="nounderline abstract_t">Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581.</a></li><li><a class="nounderline abstract_t">Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883.</a></li><li><a class="nounderline abstract_t">Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317.</a></li><li><a class="nounderline abstract_t">Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367:329.</a></li><li><a class="nounderline abstract_t">Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128.</a></li><li><a class="nounderline abstract_t">Page RL 2nd, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation 2005; 111:230.</a></li><li class="breakAll">Wynn GH, Oesterheld JR, Cozza KL, Armstrong SC. Clinical manual of drug interaction principles for medical practice, American psychiatric publishing, Washington DC 2009.</li></ol></div><div id="topicVersionRevision">Topic 3530 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31548031" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143252" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18251036" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15371689" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9636449" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8037132" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk/benefit ratio of perioperative OKT3 in cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2100991" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14974943" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lymphomas after solid organ transplantation: a collaborative transplant study report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699160" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1661608" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343955" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neoplastic disease after heart transplantation: single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15797738" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297433" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Immunosuppressive T-cell antibody induction for heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18852661" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221486" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221159" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence and prognosis of cancer following heart transplantation using RATG induction therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17346628" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421481" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16732169" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Alemtuzumab (Campath-1H): a systematic review in organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889126" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686762" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11267373" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9730427" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9361242" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9730426" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10226898" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686761" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16563974" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20643330" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11211198" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9734496" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20164816" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The KDIGO clinical practice guidelines for the care of kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23792500" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16628123" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Therapeutic drug monitoring of mycophenolate mofetil in transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19345081" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients--a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060847" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12194926" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19753679" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Two sampling time profiles for the abbreviated estimation  of mycophenolic acid area under the curve in adult  renal transplant recipients treated with mycophenolate  mofetil and concomitant tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958670" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Limited sampling strategy for the estimation of mycophenolic acid area under the curve in Tunisian renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958670" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Limited sampling strategy for the estimation of mycophenolic acid area under the curve in Tunisian renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16890114" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18555088" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27021063" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941535" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29746396" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16611334" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18926406" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262845" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19295318" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17537118" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Surgical wound-healing complications in heart transplant recipients treated with rapamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559956" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sirolimus-associated pneumonitis in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17543794" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sirolimus-induced alveolar hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16962483" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32558174" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433101" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25041227" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571342" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Successful withdrawal of corticosteroids in heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7727461" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571341" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Initial success of steroid weaning late after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18673374" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8913922" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3305832" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919619" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17713429" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17346627" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534470" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386615" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364861" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16297793" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15019657" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16939514" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488377" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30884079" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Comparing everolimus-based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from six months after heart transplantation: the randomized MANDELA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12944570" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742978" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Use of rapamycin slows progression of cardiac transplantation vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18025531" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15233824" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434506" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249734" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800227" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sirolimus for Kaposi's sarcoma in renal-transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22830463" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sirolimus and secondary skin-cancer prevention in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821896" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657387" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Drug therapy in the heart transplant recipient: part IV: drug-drug interactions.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
